Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
BioSkryb Genomics
AddedFeb 17, 2024
UpdatedJun 18, 2026
BioSkryb Genomics

BioSkryb Genomics

Series A

BioSkryb Genomics: Transforming single cell discovery with advanced genomic tools for disease management.

HQ
Durham, NC, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Founded in Durham, North Carolina, BioSkryb Genomics is dedicated to revolutionizing single cell molecular discovery and analysis. The company's core mission is to provide advanced genomic tools that enable scientists and clinicians to gain a comprehensive understanding of the genome, transcriptome, and proteome within individual cells. Their primary products include single cell whole genome and whole transcriptome amplification tools, which are pivotal for advancing research in complex disease mechanisms and management.

BioSkryb Genomics has garnered attention from notable investors and industry leaders, contributing to its rapid growth and innovation in the field. The company's cutting-edge technologies have significantly impacted genomic research, providing unprecedented insights into cellular functions and disease pathways. Through their pioneering efforts, BioSkryb Genomics continues to shape the future of molecular biology and personalized medicine.

BioSkryb Genomics - Similar Companies

Singular Genomics logo

Singular Genomics

Scribe Biosciences logo

Scribe Biosciences

Streamline Genomics logo

Streamline Genomics

Data Driven Bioscience logo

Data Driven Bioscience

10x Genomics logo

10x Genomics

10xgenomics.com

Spatial Genomics logo

Spatial Genomics

Genome Insight logo

Genome Insight

Element Biosciences logo

Element Biosciences

Nest Genomics logo

Nest Genomics

nestgenomics.com

Genomenon logo

Genomenon

genomenon.com

GenomeNext logo

GenomeNext

MicroPure Genomics logo

MicroPure Genomics

BioDatomics logo

BioDatomics

biodatomics.com

Parse Biosciences logo

Parse Biosciences

Bionano Genomics logo

Bionano Genomics

bionano.com

BioSkryb Genomics - Quick Facts

Who are BioSkryb Genomics' competitors?

Companies similar to BioSkryb Genomics include Singular Genomics, Scribe Biosciences, Streamline Genomics and Data Driven Bioscience.

When was BioSkryb Genomics founded?

BioSkryb Genomics was founded in 2018.

Where is BioSkryb Genomics' headquarters located?

BioSkryb Genomics' headquarters is located in Durham, NC, US.

When was BioSkryb Genomics' last funding round?

BioSkryb Genomics' most recent funding round was for $10M (USD) in March 2022.

How much has BioSkryb Genomics raised to-date?

As of Mar 3, 2022, BioSkryb Genomics has raised a total of $31.5M (USD).

How many employees does BioSkryb Genomics have?

BioSkryb Genomics has 83 employees as of Feb 4, 2024.

BioSkryb Genomics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Genomic Tools
Tags
  • Data Information
  • Healthtech
  • Research
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software